Format

Send to

Choose Destination
Br J Cancer. 2016 Nov 8;115(10):1174-1178. doi: 10.1038/bjc.2016.333. Epub 2016 Oct 18.

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.

Author information

1
Department of Obstetrics and Gynaecology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
2
Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
3
Department of Obstetrics and Gynaecology, Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
4
Department of Obstetrics and Gynaecology, Netherlands Cancer Institute NKI-AVL, Amsterdam, The Netherlands.
5
Department of Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, The Netherlands.
6
Department of Clinical Genetics, VU Medical Centre, Amsterdam, The Netherlands.
7
Center for Gynecologic Oncology, Academic Medical Centre, Amsterdam, The Netherlands.
8
Foundation for the Detection of Hereditary Tumours (STOET), Leiden, The Netherlands.
9
Department of Obstetrics and Gynaecology, Maastricht University Medical Centre, Maastricht, The Netherlands.
10
Department of Obstetrics and Gynaecology, Leiden University Medical Centre, Leiden, The Netherlands.
11
Department Gynaecological Oncology, UMC Utrecht Cancer Centre, Utrecht, The Netherlands.
12
Department of Obstetrics and Gynaecology, Bravis Hospital, Bergen op Zoom, The Netherlands.

Abstract

BACKGROUND:

It is unknown whether a history of breast cancer (BC) affects the outcome of BRCA1/2-associated epithelial ovarian cancer (EOC). This was investigated in the current analysis.

METHODS:

We included 386 BRCA1/2-associated EOC patients diagnosed between 1980 and 2015. Progression-free survival (PFS), progression-free interval (PFI), overall survival (OS) and ovarian cancer-specific survival (OCSS) were compared between EOC patients with and without previous BC.

RESULTS:

BRCA-associated EOC patients with, vs without, a BC history had a significantly worse PFS and PFI (multivariate hazard ratio (HRmult) 1.47; 95% confidence interval (CI) 1.03-2.08 and HRmult 1.43; 95% CI 1.01-2.03), and a non-significantly worse OS (HRmult 1.15; 95% CI 0.84-1.57) and OCSS (HRmult 1.18; 95% CI 0.85-1.62). Ovarian cancer-specific survival was significantly worse for the subgroup treated with adjuvant chemotherapy for BC (HRmult 1.99; 95% CI 1.21-3.31).

CONCLUSIONS:

Our results suggest that BRCA1/2-associated EOC patients with a previous BC have a worse outcome than EOC patients without BC, especially when treated with adjuvant chemotherapy.

PMID:
27755534
PMCID:
PMC5104898
DOI:
10.1038/bjc.2016.333
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center